Pharmacokinetic study of cephradine in pakistani healthy male volunteers

Pakistan Journal of Pharmaceutical Sciences

Volumn 21, Issue 4, 2008, Pages 400-406

  Shoaib, Muhammad Harris ^a   Shaikh, Dilnawaz ^b   Yousuf, Rabia Ismail ^a   Naqvi, Baqir S ^a   Hashmi, Khursheed ^c  

^a UNIVERSITY OF KARACHI   (Pakistan)

^b HAMDARD UNIVERSITY   (Pakistan)

^c DOW UNIVERSITY OF HEALTH SCIENCES   (Pakistan)

Author keywords

Cephradine; Pharmacokinetics

Indexed keywords

ANTIINFECTIVE AGENT; CEFRADINE;

ADULT; ARTICLE; ASIAN; BIOLOGICAL MODEL; BLOOD; CLINICAL TRIAL; HUMAN; MALE; MICROCAPSULE; ORAL DRUG ADMINISTRATION; PAKISTAN;

ADMINISTRATION, ORAL; ANTI-BACTERIAL AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CAPSULES; CEPHRADINE; HUMANS; MALE; MODELS, BIOLOGICAL; PAKISTAN; YOUNG ADULT;

EID: 58149232870     PISSN: 1011601X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Adam D, Hofsetter AG, Jacoby W and Reichart B (1976). Studies on the diffusion of Cephradine and Cephalothin into human tissues. Infection, 4(Suppl 2): S105-S107.
2. Bill NJ and Washington JA (1977). Comparison of invitro activity of Cephalexin, Cephradine and Cefaclor. Antimicrob. Agents Chemother., 11: 470-474.
3. London, UK: Stationary Office London British Pharmacopoeia (B.P.). London, UK: Stationary Office London; 2004.
4. Burroughs VJ, Maxey RW and Levy RA (2002). Racial and ethnic differences in response to medicines: towards individualized pharmaceutical treatment. J. Natl. Med. Assoc., 94(10, Suppl.): 1-26.
5. Committee ICoHS (1998). Guidance on ethnic factors in the acceptability of foreign clinical data; availability. Fed. Regist., 63(111): 31790-31796.
6. Desai NK, Sheth UK, Mucklow JC, Fraser HS, Bulpitt CJ, Jones SW and Dollery CT (1980). Antipyrine clearance in Indian villagers. Br. J. Clin. Pharmacol., 9(4): 387-394.
7. Dolfini JE, Applegate HE, Bach G, Basch H, Bernstein J, Schwartz J and Weisenborn FL (1971). A new class of semisynthetic Penicillins and Cephalosporins derived from D-2-(1, 4 - Cyclohexadienyl), glycine. J. Med. Chem., 14: 117-119.
8. Dollery CT, Fraser HS, Mucklow JC and Bulpitt CJ (1979). Contribution of environmental factors to variability in human drug metabolism. Drug Metab, Rev., 9(2): 207-220.
9. Fleisher D, Li C, Zhou Y, Pao LH and Karim A (1999). Drug, meal and formulation interactions influencing drug absorption after oral administration. Clin. Pharmacokinet., 36(3): 233-254.
10. Frackiewicz EJ, Sramek JJ, Herrera JM, Kurtz NM and Cutler NR (1997). Ethnicity and antipsychotic response. Ann. Pharmacother., 31(11): 1360-1369.
11. Ginsburg CM and McCracken GH Jr (1979). Pharmacokinetics of Cephradine suspension in infants and children. Antimicrob. Agents Chemother., 16: 74-76.
12. Kalow W and Bertilsson L (1994). Interethnic factors affecting drug response. Adv. Drug Res., 25: 1-53.
13. Kalow W (2001). Interethnic differences in drug response. In: Kalow W, Meyer UA, Tyndale RF, eds. Pharmacogenomics. Marcel Dekker, New York, pp. 109-134.
14. Kim K, Johnson JA and Derendorf H (2004). Differences in Drug Pharmacokinetics Between East Asians and Caucasians and the Role of Genetic Polymorphisms. J. Clin. Pharmacol., 44: 1083-1105.
15. Klastersky J, Daneua D and Weerts D (1973). Cephradine: antibacterial activity and clinical effectiveness. Chemotherapy, 18: 191-204.
16. Kucers A, CroweSM, Graysons ML and Hoy JF (1997). The Use of Antibiotics. A clinical Review of Antibacterial, Antifungal and Antiviral Drugs, Fifth Edition, pp. 28, 272-281.
17. Miraglia GJ, Renz KJ and Gadebusch HH (1973). Comparison of the chemotherapeutic and Pharmacodynamic activities of Cephradine, Cephalothin and Cephaloridine in mice. Antimicrob. Agents Chemother., 3: 270-273.
18. Mollering RC Jr and Swartz MN (1976). Drug Therapy. The newer Cephalosporins. New England J. Med., 294: 24-28.
19. Mucklow JC, Fraser HS, Bulpitt CJ, Kahn C, Mould G and Dollery CT (1979). Environmental factors affecting antipyrinemetabolism in London factory and office workers. Br. J. Clin. Pharmacol., 7(3): 237-243.
20. Neiss ES (1973). Cephradine - a summary of preclinical studies and clinical pharmacology. J. Irish Med. Assoc., 66 (Suppl 6): 1-12.
21. Nightingale CH, Greene DD and Quintilliani R (1975). Pharmacokinetics and clinical use of cephalosporin antibiotics. J. Pharm. Sci., 64: 1899-1927.
22. Rattie ES, Bernardo PD and Ravin LJ (1976). Pharmacokinetic interpretation of Cephradine levels in serum after intravenous and extravascular administration in humans. Antimicrob. Agents Chemother., 10(2): 283-287.
23. Ritschel WA (1992). Hand Book of Basic Pharmacokinetics. Fourth edition. Drug Intelligence Publication Inc. Hamilton USA, 536-545.
24. Simon C, Malerczyk V, Brahmstaedt E and Toeller W (1973). Cefazolin, a new broad-spectrum antibiotic. Dent. Med. Wochenschr., 98: 2448-2450.
25. Smith MW and Mendoza RP (1996). Ethnicity and pharmacogenetics. Mt. Sinai J. Med., 63(5-6): 285-290.
26. Thomas JA (1995). Drug-nutrient interactions. Nutr. Rev., 53(10): 271-282.
27. Tschanz C, Stargel WW and Thomas JA (1996). Interactions between drugs and nutrients. Adv. Pharmacol., 35: 1-26.
28. Weliky I and Zoki A (1973). Eighth International Congress of Chemotherapy, Athens, Greece.
29. Wood AJ and Zhou HH (1991). Ethnic differences in drug disposition and responsiveness. Clin. Pharmacokinet., 20(5): 350-373.
30. Zaki AEC, Schreiber IW, Knill JR and Hubsher JA (1974). Clinical pharmacology of oral cephradine. J. Clin. Pharmacol., 14: 118-126.